688443 Stock Overview
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Chongqing Genrix Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥39.80 |
| 52 Week High | CN¥44.50 |
| 52 Week Low | CN¥24.16 |
| Beta | 0 |
| 1 Month Change | -1.17% |
| 3 Month Change | 38.00% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 16.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688443 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.2% | 3.5% | 4.4% |
| 1Y | n/a | -22.5% | -12.6% |
Return vs Industry: Insufficient data to determine how 688443 performed against the CN Biotechs industry.
Return vs Market: Insufficient data to determine how 688443 performed against the CN Market.
Price Volatility
| 688443 volatility | |
|---|---|
| 688443 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688443's share price has been volatile over the past 3 months.
Volatility Over Time: 688443's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 392 | n/a | www.genrixbio.com |
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
Chongqing Genrix Biopharmaceutical Co., Ltd. Fundamentals Summary
| 688443 fundamental statistics | |
|---|---|
| Market cap | CN¥14.59b |
| Earnings (TTM) | -CN¥801.32m |
| Revenue (TTM) | CN¥1.21m |
Over9,999x
P/S Ratio-18.2x
P/E RatioIs 688443 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688443 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.21m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥1.21m |
| Other Expenses | CN¥802.53m |
| Earnings | -CN¥801.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -66,142.63% |
| Debt/Equity Ratio | 21.6% |
How did 688443 perform over the long term?
See historical performance and comparison